Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for one medicine.
Adalimumab (Humira) is recommended as an option for use to treat moderate-to-severe ulcerative colitis in children aged 6 years and older, when other treatments have not worked or are not suitable for them.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.